Antibiotic-sparing strategies for multidrug-resistant organism (MDRO) infections
Frontiers in Pharmacology · 29.09.2025 · 16
DOI: 10.3389/fphar.2025.1653424 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 29.09.2025. Verfasst von Shuai Geng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Ninth Medical Center of PLA General Hospital, Beijing, China. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The global rise of multidrug-resistant organisms (MDROs), such as carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA), has rendered conventional antibiotics increasingly ineffective, particularly in intensive care units (ICUs) where mortality rates exceed 50% in severe infections. Overuse of broad-spectrum antibiotics accelerates resistance while disrupting host microbiota, necessitating innovative “antibiotic-sparing” strategies. This review synthesizes three pillars of intervention: (1) non-antibiotic therapies, including bacteriophages for targeted pathogen lysis, monoclonal antibodies (e.g., BiS4αPa against Pseudomonas aeruginosa ), and nanotechnology-enhanced antimicrobial peptides (AMPs) for biofilm disruption; (2) antimicrobial stewardship integrating rapid diagnostics (MALDI-TOF, mNGS), PK/PD-guided dosing, and short-course regimens (7-day therapy validated by RCTs); and (3) transmission prevention through UV-C disinfection, AI-driven hygiene compliance, and gut microbiota modulation. Key innovations include phage-antibiotic synergies, bispecific antibody engineering, and dynamic PK/PD-TDM frameworks. Despite challenges in clinical translation and cost-effectiveness, these strategies collectively reduce antibiotic reliance, mitigate resistance evolution, and offer a paradigm shift toward precision infection control. Future directions emphasize combinatorial therapies, regulatory harmonization, and scalable environmental-behavioral interventions to address the post-antibiotic era crisis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, The Ninth Medical Center of PLA General Hospital, Beijing, China.
Zitieren
APA
Geng, S., Tang, Q., & Shi, N. (2025). Antibiotic-sparing strategies for multidrug-resistant organism (MDRO) infections. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1653424
Vancouver
Geng S, Tang Q, Shi N. Antibiotic-sparing strategies for multidrug-resistant organism (MDRO) infections. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1653424
BibTeX
@article{Geng2025,
author = {Geng, Shuai and Tang, Qing and Shi, Ning},
title = {Antibiotic-sparing strategies for multidrug-resistant organism (MDRO) infections},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1653424}
}
EUVIMED